Ketamine Tablet in Pediatric Patients

Ketamine tablet in pediatric patients has a longer clinical history than its psychiatric applications — dating to the 1980s when it was used as a premedication for pediatric procedures. For the broader historical context, see our article on the history of ketamine tablets. More recently, pediatric psychiatric applications have emerged, though the evidence base remains limited and the regulatory landscape requires careful navigation.

Historical Context: Pediatric Anesthetic Premedication

The longest-standing evidence base for ketamine tablet in children is in anesthesia premedication — a single dose given 20–30 minutes before induction to sedate anxious children and facilitate smooth separation from parents.

Why Oral Was Preferable in Pediatric Anesthesia

For children requiring surgery or diagnostic procedures, IV placement is itself a significant source of anxiety and distress. The oral route offered:

• Needle-free medication delivery
• Administration in a familiar environment (the ward room or family waiting area) — the same principle that makes at-home tablet therapy appealing for adults today
• Parental presence during medication administration
• Acceptability by children who would take an oral medication but strongly resist injections

Key Pediatric Anesthetic Studies

Gutstein et al. (1992): One of the earliest systematic evaluations of ketamine tablet for pediatric premedication. Children received 3–6 mg/kg orally and demonstrated adequate sedation within 20–30 minutes. Bioavailability in this pediatric study was estimated at approximately 20–25%, similar to adults.

Malinovsky et al. (1996): Detailed pharmacokinetic characterization in children undergoing surgery. Ketamine tablet 6 mg/kg produced sedation adequate for IV placement in 12 of 16 children within 20–30 minutes. Bioavailability ranged from 16–29% — wide variability attributed to gastric pH differences and individual metabolic variability.

Funk et al. (1996): Compared ketamine tablet premedication to oral midazolam in children. Both produced acceptable preoperative anxiolysis, with ketamine perhaps slightly superior in children with extreme procedural anxiety.

These studies collectively established that ketamine tablet at 3–6 mg/kg was effective for pediatric premedication with an acceptable safety profile in anesthetic settings. However, this use has declined somewhat as other oral premedication options (midazolam, dexmedetomidine) have become available.

Pediatric Pharmacokinetics

Pharmacokinetics in children differ from adults in several ways relevant to ketamine tablet:

Faster gastric emptying: Children generally have faster gastric emptying than adults, contributing to faster absorption kinetics. Onset may be slightly faster in children than adults at the same mg/kg dose.

Higher proportion of body water: Children have higher total body water and lower fat percentage relative to adults. Ketamine's distribution volume may differ slightly, affecting half-life.

Hepatic enzyme maturation: CYP3A4 (the primary ketamine-metabolizing enzyme) is not fully mature until approximately age 6–12 months. Neonates and very young infants have significantly lower CYP3A4 activity, resulting in higher ketamine bioavailability — an important consideration for very young patients.

Variability: Published pediatric pharmacokinetic data shows high inter-individual variability (similar to adults), with bioavailability ranging from 16–29% across studies.

Emerging Pediatric Psychiatric Applications

Beyond anesthetic premedication, ketamine tablet is beginning to be explored for psychiatric indications in adolescents, though the evidence base is extremely limited.

Adolescent Depression

Treatment-resistant depression in adolescents — those who have failed SSRIs and other standard treatments — is a growing clinical challenge with significant suicide risk. The FDA-approved treatments for adolescent depression are limited (fluoxetine and escitalopram for ages 12+; SSRIs generally), and there is no ketamine product approved for pediatric psychiatric use.

Available evidence:

• Case reports and case series describe beneficial responses to IV ketamine in adolescents with severe TRD, with similar response rates to adults
• No randomized controlled trials of ketamine tablet for adolescent depression have been published
• One ongoing clinical trial (as of 2024) is examining IV ketamine in adolescents; results will inform oral protocols

Clinical use: Some child and adolescent psychiatrists at academic medical centers have begun offering IV ketamine to adolescents (ages 12–17) with severe TRD under careful protocols. Ketamine tablet is being used in some specialized practices for adolescent maintenance, but this remains a small and highly specialized practice without standardized protocols.

Pediatric Chronic Pain

Pediatric chronic pain conditions — CRPS, neuropathic pain from cancer treatment, fibromyalgia-like syndromes — affect a meaningful minority of children and adolescents. Ketamine tablet at low doses has been used in some pediatric pain programs for refractory pediatric chronic pain, typically following similar low-dose protocols adapted from adult pain management.

Evidence: Primarily case reports and small series from pediatric pain centers. Systematic research is lacking.

Regulatory and Ethical Considerations

FDA Status

Ketamine (Ketalar) is FDA-approved as an anesthetic for patients of all ages. However, no ketamine product is FDA-approved for psychiatric use in pediatric patients. The FDA's current approved age ranges for Spravato begin at 18 years. Off-label use in adolescents must be carefully justified.

Informed Consent/Assent

For pediatric patients, both parental informed consent AND the adolescent patient's assent (for ages typically 12+) are ethically required. The informed consent discussion must cover:

• The off-label nature of the use
• Lack of long-term safety data in this age group
• Developmental considerations (adolescent brain development and any possible long-term effects of ketamine on developing brains)
• Alternatives that have not been tried

Developing Brain Considerations

An important theoretical concern is the effect of ketamine on developing brains. Animal research has shown that NMDA receptor antagonism during critical developmental periods can cause apoptosis (programmed cell death) in developing neurons. This has raised concerns about anesthetic use in very young children, and the same theoretical risk applies to ketamine.

The clinical significance of this finding in adolescents (rather than neonates, where the risk appears greatest) is less clear. The dose and frequency of ketamine in psychiatric protocols is different from anesthesia, and the risk-benefit calculus for a severely depressed adolescent may favor treatment. However, this remains a genuine consideration requiring transparent discussion with families.

Dosing in Pediatric Patients

For the anesthetic premedication indication (established evidence):

• Dose: 3–6 mg/kg orally, 20–30 minutes before procedure
• Maximum: Usually capped at 250–300 mg total dose

For emerging psychiatric use in adolescents (highly individualized, limited evidence):

• Starting dose: Often lower than adult starting doses (0.5–1 mg/kg)
• Titration: More conservative than adults given limited data
• Formulation: Oral solution is preferable in younger adolescents; tablets in older adolescents who can swallow them

Contraindications in Pediatric Patients

Additional contraindications relevant to pediatric populations:

• Age <2 years: Insufficient safety data; generally avoided for psychiatric indications
• Airway concerns: Ketamine increases oral secretions; younger children may have upper airway risk
• Psychotic features: Even more carefully evaluated in adolescents with emerging psychosis
• Substance use history: Adolescents with comorbid substance use disorders require careful risk assessment

Summary: Where Pediatric Ketamine Tablet Stands

Ketamine tablet in pediatric patients has an established, evidence-based role in anesthetic premedication that is well-characterized. Psychiatric applications in adolescents are emerging but remain investigational, with very limited evidence and significant developmental safety questions. The appropriate setting for any pediatric psychiatric ketamine use is academic medical centers with specialized expertise in both pediatric psychiatry and ketamine pharmacology, with rigorous informed consent processes.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service
• NIMH: Children and Mental Health — National Institute of Mental Health information on mental health disorders in children and adolescents